AR121261A1 - CHO CELL EXPRESSING HET IL-15 - Google Patents

CHO CELL EXPRESSING HET IL-15

Info

Publication number
AR121261A1
AR121261A1 ARP210100285A ARP210100285A AR121261A1 AR 121261 A1 AR121261 A1 AR 121261A1 AR P210100285 A ARP210100285 A AR P210100285A AR P210100285 A ARP210100285 A AR P210100285A AR 121261 A1 AR121261 A1 AR 121261A1
Authority
AR
Argentina
Prior art keywords
heterodimer
polypeptide
human interleukin
human
cho cell
Prior art date
Application number
ARP210100285A
Other languages
Spanish (es)
Inventor
Richard Gabriel
Thomas Jostock
Justyna Jozefczuk
Urs Ulrich Lohrig
Alexandre Aurlien Pons
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR121261A1 publication Critical patent/AR121261A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1793—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2086—IL-13 to IL-16
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation

Abstract

La presente se refiere al heterodímero de IL-15 / IL-15Ra producido en una línea celular CHO, y método de producción del heterodímero y método de tratamiento utilizando el heterodímero. Reivindicación 1: Un complejo polipeptídico que comprende un polipéptido de interleucina 15 humana (IL-15) y un polipéptido del receptor a de interleucina 15 humana (IL-15Ra), en donde el complejo polipeptídico comprende glicanos unidos a N que comprenden FA2G2, FA2G2S1, FA2G2S2, FA3G3S1, FA2F1G2S2, FA3G2S2, y FA3G3S3. Reivindicación 13: Un heterodímero de IL-15 / IL-15Ra aislado producido en una célula no humana, en donde el heterodímero de IL-15 / IL-15Ra comprende a(2,6) sialilación unida a O. Reivindicación 18: Una composición farmacéutica que comprende el complejo polipeptídico de cualquiera de las reivindicaciones 1 - 12 o el heterodímero IL-15 / IL-15Ra aislado de cualquiera de las reivindicaciones 13 - 17. Reivindicación 20: Una célula no humana que comprende ácidos nucleicos que codifican un polipéptido de interleucina 15 (IL-15) humana y un polipéptido del receptor a de interleucina 15 humana (IL-15Ra), en donde la IL-15 y la IL-15Ra expresadas por la célula forman un heterodímero, y en donde el heterodímero comprende sialilación unida a a(2,6). Reivindicación 23: Un método para tratar el cáncer, que comprende administrar a un sujeto que necesite la composición farmacéutica de la reivindicación 18 ó 19.The present relates to IL-15 / IL-15Ra heterodimer produced in a CHO cell line, and method of production of the heterodimer and method of treatment using the heterodimer. Claim 1: A polypeptide complex comprising a human interleukin 15 (IL-15) polypeptide and a human interleukin 15 receptor a (IL-15Ra) polypeptide, wherein the polypeptide complex comprises N-linked glycans comprising FA2G2, FA2G2S1 , FA2G2S2, FA3G3S1, FA2F1G2S2, FA3G2S2, and FA3G3S3. Claim 13: An isolated IL-15/IL-15Ra heterodimer produced in a non-human cell, wherein the IL-15/IL-15Ra heterodimer comprises O-linked (2,6) sialylation. Claim 18: A composition pharmaceutical comprising the polypeptide complex of any of claims 1-12 or the isolated IL-15 / IL-15Ra heterodimer of any of claims 13-17. Claim 20: A non-human cell comprising nucleic acids encoding a polypeptide of human interleukin 15 (IL-15) and a human interleukin 15 receptor a (IL-15Ra) polypeptide, wherein IL-15 and IL-15Ra expressed by the cell form a heterodimer, and wherein the heterodimer comprises sialylation attached to a(2,6). Claim 23: A method of treating cancer, comprising administering to a subject in need of the pharmaceutical composition of claim 18 or 19.

ARP210100285A 2020-02-05 2021-02-03 CHO CELL EXPRESSING HET IL-15 AR121261A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202062970485P 2020-02-05 2020-02-05

Publications (1)

Publication Number Publication Date
AR121261A1 true AR121261A1 (en) 2022-05-04

Family

ID=74554194

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210100285A AR121261A1 (en) 2020-02-05 2021-02-03 CHO CELL EXPRESSING HET IL-15

Country Status (21)

Country Link
US (1) US20210244821A1 (en)
EP (1) EP4100425A1 (en)
JP (2) JP2022522566A (en)
KR (1) KR20220137651A (en)
CN (1) CN115023436A (en)
AR (1) AR121261A1 (en)
AU (1) AU2021215893A1 (en)
BR (1) BR112022014493A2 (en)
CA (1) CA3168469A1 (en)
CL (2) CL2022002094A1 (en)
CO (1) CO2022010860A2 (en)
CR (1) CR20220367A (en)
DO (1) DOP2022000156A (en)
EC (1) ECSP22060286A (en)
IL (1) IL295278A (en)
JO (1) JOP20220174A1 (en)
MX (1) MX2022009611A (en)
PE (1) PE20221509A1 (en)
TW (1) TW202142558A (en)
UY (1) UY39062A (en)
WO (1) WO2021156720A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023550880A (en) 2020-10-26 2023-12-06 サイチューン ファーマ IL-2/IL-15Rβγ agonist for treating non-melanoma skin cancer
CA3195627A1 (en) 2020-10-26 2022-05-05 Stefano FERRARA Il-2/il-15r.beta..gamma. agonist for treating squamous cell carcinoma

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL71691A (en) 1984-04-27 1991-04-15 Yeda Res & Dev Production of interferon-ypsilon
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
TW402639B (en) 1992-12-03 2000-08-21 Transkaryotic Therapies Inc Protein production and protein delivery
US6569681B1 (en) 2000-03-14 2003-05-27 Transkaryotic Therapies, Inc. Methods of improving homologous recombination
PT1899364T (en) 2005-05-17 2020-05-20 Univ Connecticut Compositions and methods for immunomodulation in an organism
WO2007070488A2 (en) 2005-12-12 2007-06-21 The Cbr Institute For Biomedical Research, Inc. Integrin alpha l i domain mutants with increased binding affinity
CA2636111C (en) * 2006-01-13 2018-04-03 The Government Of The United States, As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health Codon optimized il-15 and il-15r-alpha genes for expression in mammalian cells
IL182956A0 (en) * 2007-05-03 2008-01-20 Yeda Res & Dev Glycan modified soluble receptors and binding proteins and their use
PT2160401E (en) 2007-05-11 2014-10-30 Altor Bioscience Corp Fusion molecules and il-15 variants
EP2326531B2 (en) 2008-08-22 2021-01-13 Magna Seating Inc. Disc recliner with reduced backlash
TWI604850B (en) * 2009-10-05 2017-11-11 菲瑞茵國際中心股份有限公司 Pharmaceutical preparation
AU2011305476B2 (en) 2010-09-21 2016-12-01 Altor Bioscience Corporation Multimeric IL-15 soluble fusion molecules and methods of making and using same
US20150359853A1 (en) * 2012-10-24 2015-12-17 Admune Therapeutics Llc Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes
PL3536776T3 (en) 2014-04-29 2024-03-25 Novartis Ag Novel vertebrate cells and methods for recombinantly expressing a polypeptide of interest
PT3235830T (en) * 2014-12-19 2020-10-06 Jiangsu Hengrui Medicine Co Interleukin 15 protein complex and use thereof
JP7200104B2 (en) * 2016-08-01 2023-01-06 ヴァイロジン バイオテック カナダ リミテッド Oncolytic Herpes Simplex Virus Vectors Expressing Immune System Stimulatory Molecules
JP2019533449A (en) * 2016-10-21 2019-11-21 アルター・バイオサイエンス・コーポレーション Molecules based on multimeric IL-15
AU2018208883B2 (en) * 2017-01-20 2021-02-11 Novartis Ag Combination therapy for the treatment of cancer
EP3746104A1 (en) * 2018-02-02 2020-12-09 Novartis AG Combination of sting agonist and il-15/il15-ra for the treatment of cancer
AU2019226387A1 (en) * 2018-03-01 2020-08-20 Glycotope Gmbh Fusion protein constructs comprising an anti-MUC1 antibody and IL-15

Also Published As

Publication number Publication date
WO2021156720A1 (en) 2021-08-12
TW202142558A (en) 2021-11-16
BR112022014493A2 (en) 2022-09-20
JP2023145622A (en) 2023-10-11
MX2022009611A (en) 2022-11-07
UY39062A (en) 2021-09-30
ECSP22060286A (en) 2022-09-30
JP2022522566A (en) 2022-04-20
US20210244821A1 (en) 2021-08-12
CR20220367A (en) 2022-08-30
CL2023002447A1 (en) 2024-03-15
CO2022010860A2 (en) 2022-08-19
IL295278A (en) 2022-10-01
DOP2022000156A (en) 2022-10-16
PE20221509A1 (en) 2022-10-04
KR20220137651A (en) 2022-10-12
CA3168469A1 (en) 2021-08-12
CL2022002094A1 (en) 2023-03-10
JOP20220174A1 (en) 2023-01-30
AU2021215893A1 (en) 2022-08-25
EP4100425A1 (en) 2022-12-14
CN115023436A (en) 2022-09-06

Similar Documents

Publication Publication Date Title
AR121261A1 (en) CHO CELL EXPRESSING HET IL-15
Vogt et al. Mosquito saliva alone has profound effects on the human immune system
Brotas et al. Tumor necrosis factor-alpha and the cytokine network in psoriasis
De Simone et al. Role of TH17 cytokines in the control of colorectal cancer
Pappu et al. Regulation of epithelial immunity by IL-17 family cytokines
Lee et al. Blockade of IL-33/ST2 ameliorates airway inflammation in a murine model of allergic asthma
Xing et al. Th9: a new player in asthma pathogenesis?
Yan et al. T cells are required for orthodontic tooth movement
Gunderson et al. CD8+ T cells mediate RAS-induced psoriasis-like skin inflammation through IFN-γ
CL2016001113A1 (en) Method for the production of infertile fish and aquatic animals that produce eggs and for the administration of compounds in eggs and embryos
JP2009515909A5 (en)
CN106429362B (en) Prepared slices of Chinese crude drugs intelligence prescription system
Belladonna et al. Bioengineering heterodimeric cytokines: turning promiscuous proteins into therapeutic agents
Acevedo Saliva and oral health
MX2015017852A (en) Therapeutic agent comprising humanized anti-epiregulin antibody as active ingredient for non-small-cell lung carcinoma excluding adenocarcinoma.
Khalil et al. Implications of a ‘Third Signal’in NK cells
Kim et al. Colonization and effector functions of innate lymphoid cells in mucosal tissues
Zhang et al. Blockade of IL-6 signal exacerbates acute inflammatory bowel disease via inhibiting IL-17 producing in activated CD4+ Th17 population.
Mitoma et al. Characterization of bovine interleukin-2 stably expressed in HEK-293 cells
Sfontouris et al. Effect of granulocyte-macrophage colony-stimulating factor (GM-CSF) on pregnancy rates in patients with multiple unsuccessful IVF attempts
Aioi et al. IL-27 regulates cytokine production as a double-edged sword in keratinocytes
Jian et al. Promoted Generation of T Helper 1-Like Regulatory T Cells After Transient Middle Cerebral Artery Occlusion in Type-2 Diabetic Mice
Chovar-Vera et al. Dopaminergic Signalling Enhances IL-2 Production and Strengthens Anti-Tumour Response Exerted by Cytotoxic T Lymphocytes in a Melanoma Mouse Model
Labanchi Vacunación con EG95 contra la equinococosis quística ovina en la provincia de Río Negro: análisis de 12 años de trabajo
Veldman et al. Stem cells on fire: inflammatory signaling in HSC emergence